Breaking News Instant updates and real-time market news.

VRX

Valeant

$17.00

-0.1598 (-0.93%)

, TKPYY

Takeda Pharmaceutical Co. Ltd.

$20.97

-0.035 (-0.17%)

10:01
11/30/16
11/30
10:01
11/30/16
10:01

Valeant talks to sell Salix to Takeda for about $10B break down, DJ reports

VRX

Valeant

$17.00

-0.1598 (-0.93%)

TKPYY

Takeda Pharmaceutical Co. Ltd.

$20.97

-0.035 (-0.17%)

  • 13

    Dec

  • 14

    Dec

  • 16

    Feb

VRX Valeant
$17.00

-0.1598 (-0.93%)

11/18/16
DBAB
11/18/16
NO CHANGE
Target $24
DBAB
Hold
Deutsche still likes near-term setup for Valeant shares
Deutsche Bank analyst Gregg Gilbert said yesterday that he still likes the near-term setup for shares of Valeant Pharmaceuticals after federal prosecutors announced criminal charges against former executive Gary Tanner and the former CEO of Philidor. It is "good to see" that Valeant and other senior executives were not charged, Gilbert told investors in a research note. The charges could be an important step forward as the company and new management team distance themselves from the past, Gilbert wrote. The analyst points out that the bar for 2016 has already been lowered and that new CFO Paul Herendeen thinks of guidance as a commitment. Gilbert keeps a Hold rating on Valeant with a $24 price target. The stock closed yesterday up 12c to $17.98.
11/18/16
ADAM
11/18/16
NO CHANGE
Target $17
ADAM
Hold
Valeant negative headlines remain a risk, says Canaccord
Canaccord analyst Neil Maruoka noted yesterday's headlines regarding criminal charges against a former Valeant executive. He said although the charges are not pertinent to Valeant it underscores the negative headline risk that is associated with owning the shares. Maruoka said the company's lower guidance suggests growth headwinds into next year and believes the company still needs to sell assets to de-lever. Maruoka maintained his Hold rating and $17 price target on Valeant shares.
11/23/16
MZHO
11/23/16
DOWNGRADE
Target $11
MZHO
Underperform
Valeant downgraded to Underperform from Neutral at Mizuho
Mizuho analyst Irina Koffler downgraded Valeant Pharmaceuticals to Underperform, her firm's sell rating equivalent, and cut her price target for the shares to $11 from $25. The drugmaker closed yesterday at $17.83. Koffler believes growth challenges, 2017 guidance risk, legal overhangs and weaker asset divestitures create an unfavorable risk/reward profile. She expects the shares to trend lower over the next 6-12 months.
11/29/16
DBAB
11/29/16
NO CHANGE
Target $24
DBAB
Hold
Deutsche weighs impact on Valeant should Salix be sold
Deutsche Bank analyst Gregg Gilbert hopes to hear closure soon on a potential sale of Salix by Valeant Pharmaceuticals. While a sale is not a "no-brainer" given the unit's growth and durability, a deal could improve Valeant's debt situation and add to its value, Gilbert tells investors in a research note. His preliminary analysis suggests that a sale of Salix for $10B coupled with de-levering would be "significantly" dilutive to earnings but accretive to Valeant's value. His analysis yields earnings dilution of 26%-27% in 2018- 2021 and an increase in the company's theoretical discounted cash flow value to $32 from $24. Gilbert continues to like the near-term setup in shares of Valeant but keeps a Hold rating on the shares with a $24 price target. The pharmaceutical closed yesterday up 44c to $17.44.
TKPYY Takeda Pharmaceutical Co. Ltd.
$20.97

-0.035 (-0.17%)

06/08/16
RHCO
06/08/16
NO CHANGE
RHCO
Ultragenyx collaboration with Takeda 'exceptionally positive,' says SunTrust
After Ultragenyx (RARE) announced a development and commercialization collaboration for rare genetic diseases with Takeda (TKPYY), SunTrust says the deal terms are "exceptionally positive" for Ultragenyx. The firm notes that the latter company will receive both compounds and cash payments from Takeda, while Takeda will only get comemrcial rights in Asia. The firm keeps a Buy rating on Ultragenyx.
07/07/16
UBSW
07/07/16
INITIATION
UBSW
Neutral
Takeda Pharmaceutical initiated with a Neutral at UBS
UBS analyst Atsushi Seki started Takeda with a Neutral rating and Y4,600 price target.
09/14/16
SBSH
09/14/16
NO CHANGE
Target $4
SBSH
Neutral
Citi views Synergy Pharmaceuticals as potential target for Takeda
Citi analyst Liav Abraham calls Synergy Pharmaceuticals (SGYP) the most likely potential target for Takeda Pharmaceutical (TKPYY) among her coverage universe. The Financial Times earlier today reported that Takeda is ready to spend as much as $15B in acquisitions to expand its business in the United States. Abraham has a Neutral rating on Synergy with a $4 price target. The analyst sees Synergy as a potential target given the "extensive resources" needed to commercialize its lead asset, plecanatide, as well as Takdea's presence in the irritable bowel syndrome/chronic idiopathic constipation space. Shares of Synergy are up 6% to $5.18 in early trading.
09/15/16
WELS
09/15/16
NO CHANGE
WELS
Street underestimating potential of PRA Health deal, says Wells Fargo
Wells Fargo believes that the Street is underestimating the potential benefit to PRA Health (PRAH) of its deal with Takeda (TKPYY). The firm expects PRA's bookings over the next year to significantly exceed the industry average, causing 2017 and 2018 consensus estimates for the company to rise. Wells raised its price target on PRA to $65-$67 from $56-$59 and keeps an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

ANET

Arista Networks

$121.35

-1.27 (-1.04%)

11:07
02/22/17
02/22
11:07
02/22/17
11:07
Conference/Events
Arista Networks management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

  • 27

    Feb

  • 03

    Mar

  • 13

    Mar

  • 14

    Mar

FB

Facebook

$133.72

0.19 (0.14%)

11:06
02/22/17
02/22
11:06
02/22/17
11:06
Hot Stocks
Instagram announces update allowing sharing of multiple photos in one post »

Facebook's Instagram…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 28

    Feb

  • 06

    Mar

  • 19

    Mar

  • 28

    Mar

WMAR

West Marine

$9.15

-0.01 (-0.11%)

11:06
02/22/17
02/22
11:06
02/22/17
11:06
Conference/Events
West Marine management to meet with B. Riley »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 28

    Feb

AAP

Advance Auto Parts

$157.00

-4.155 (-2.58%)

11:06
02/22/17
02/22
11:06
02/22/17
11:06
Options
Advance Auto Parts call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMTD

TD Ameritrade

$43.28

0.13 (0.30%)

11:05
02/22/17
02/22
11:05
02/22/17
11:05
Conference/Events
TD Ameritrade management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

AMD

AMD

$14.00

0.87 (6.63%)

11:04
02/22/17
02/22
11:04
02/22/17
11:04
Conference/Events
AMD management to meet with Canaccord »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

MOBL

MobileIron

$4.90

0.15 (3.16%)

11:04
02/22/17
02/22
11:04
02/22/17
11:04
Hot Stocks
MobileIron forms Internet of Things division »

MobileIron announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

MOBL

MobileIron

$4.90

0.15 (3.16%)

11:04
02/22/17
02/22
11:04
02/22/17
11:04
Hot Stocks
MobileIron forms Internet of Things division »

MobileIron announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

AMD

AMD

$14.00

0.87 (6.63%)

11:04
02/22/17
02/22
11:04
02/22/17
11:04
Technical Analysis
AMD ticks fresh multi-year and 52-week high »

The shares were last at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

MRVL

Marvell

$16.21

0.4 (2.53%)

11:04
02/22/17
02/22
11:04
02/22/17
11:04
Conference/Events
Marvell management to meet with B. Riley »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 10

    Mar

  • 04

    Apr

  • 05

    Apr

SQ

Square

$14.70

0.07 (0.48%)

, AAPL

Apple

$136.70

0.98 (0.72%)

11:02
02/22/17
02/22
11:02
02/22/17
11:02
Earnings
On The Fly: What to watch in Square earnings report »

Square (SQ) is scheduled…

SQ

Square

$14.70

0.07 (0.48%)

AAPL

Apple

$136.70

0.98 (0.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 13

    Mar

CWBC

Community West Bancshares

$10.13

0.0252 (0.25%)

11:02
02/22/17
02/22
11:02
02/22/17
11:02
Hot Stocks
Community West Bancshares says CFO Baltuskonis to retire July 2017 »

Community West Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AFL

Aflac

$71.36

-0.06 (-0.08%)

11:02
02/22/17
02/22
11:02
02/22/17
11:02
Conference/Events
Aflac management to meet with Sandler O'Neill »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 05

    Mar

ARGS

Argos Therapeutics

$4.40

-0.3 (-6.38%)

10:56
02/22/17
02/22
10:56
02/22/17
10:56
Downgrade
Argos Therapeutics rating change  »

Argos Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 27

    Apr

CPB

Campbell Soup

$59.42

0.47 (0.80%)

10:56
02/22/17
02/22
10:56
02/22/17
10:56
Hot Stocks
Campbell Soup CEO repeats plan to achieve $300M in cost savings by end of FY17 »

Campbell Soup CEO Denise…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

TSO

Tesoro

$88.39

-0.69 (-0.77%)

10:56
02/22/17
02/22
10:56
02/22/17
10:56
Options
Tesoro put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMD

AMD

$14.00

0.87 (6.63%)

, INTC

Intel

$36.52

0.04 (0.11%)

10:53
02/22/17
02/22
10:53
02/22/17
10:53
Periodicals
AMD looks to challenge Intel's PC processor dominance, FT says »

With a new type of…

AMD

AMD

$14.00

0.87 (6.63%)

INTC

Intel

$36.52

0.04 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

  • 27

    Feb

  • 19

    Mar

  • 04

    Apr

  • 05

    Apr

CEO

CNOOC

$121.51

-1.14 (-0.93%)

10:52
02/22/17
02/22
10:52
02/22/17
10:52
Recommendations
CNOOC analyst commentary  »

CNOOC named a long…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QVCA

Liberty Interactive

$19.71

0.41 (2.12%)

10:51
02/22/17
02/22
10:51
02/22/17
10:51
Technical Analysis
Liberty Interactive spikes higher on very heavy volume »

The stock has spiked,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAA

Under Armour

$22.25

0.47 (2.16%)

10:48
02/22/17
02/22
10:48
02/22/17
10:48
Options
Under Armour calls active as shares tick higher »

Under Armour calls active…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EAT

Brinker

$42.55

-1.32 (-3.01%)

10:45
02/22/17
02/22
10:45
02/22/17
10:45
Conference/Events
Brinker management to meet with Maxim »

Field trip to company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 03

    May

KR

Kroger

$33.05

-1.175 (-3.43%)

10:41
02/22/17
02/22
10:41
02/22/17
10:41
Options
Pre-earnings jitters in Kroger as shares slide »

Pre-earnings jitters in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNP

Union Pacific

$108.18

-1.495 (-1.36%)

10:39
02/22/17
02/22
10:39
02/22/17
10:39
Hot Stocks
Breaking Hot Stocks news story on Union Pacific »

Union Pacific says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 09

    May

ECPG

Encore Capital

10:38
02/22/17
02/22
10:38
02/22/17
10:38
Periodicals
Cabot Credit considering London stock listing, Sky News reports »

Shareholders in Cabot…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

UNP

Union Pacific

$108.18

-1.49 (-1.36%)

10:38
02/22/17
02/22
10:38
02/22/17
10:38
Hot Stocks
Breaking Hot Stocks news story on Union Pacific »

Union Pacific says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 09

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.